Lupus最新文献

{"title":"Association between excess body weight and disordered eating attitude among women living with systemic lupus erythematosus.","authors":"Jhulia Cnl da Mota, Fabiana I Smaira, Juliana Maria Gonçalves Julio, Beatriz Garcia de Carvalho, Lucas M Carvalho, Amanda A Ribeiro, Leticia L Souza, Eduardo F Borba, Hamilton Roschel, Bruno Gualano, Carolina F Nicoletti","doi":"10.1177/09612033251332830","DOIUrl":"https://doi.org/10.1177/09612033251332830","url":null,"abstract":"<p><p>The study aimed to: (i) characterize dietary intake and identify disorders eating attitudes in women with SLE, (ii) evaluate possible differences in both dietary intake and disorders eating attitudes in patients with SLE according to nutritional status, (iii) investigate possible associations between eating disorders attitudes, anthropometric characteristics and food consumption.</p><p><strong>Methods: </strong>This cross-sectional study included 46 premenopausal female patients (18-40 years), with inactive disease, using prednisone <10 mg/day and hydroxychloroquine at a stable dose. Patients were allocated into two groups according to their nutritional status by body mass index (BMI): normal weight (BMI between 18.5 and 24.9 kg/m²) and excess weight (BMI >25 kg/m²). Food consumption was assessed according to the processing level and energy and macronutrient content. The Disordered Eating Attitude Scale (DEAS) was applied.</p><p><strong>Results: </strong>Patients with excess weight had a higher DEAS score when compared to those with normal weight (34 ± 8.7 vs 25 ± 5.9, <i>p</i> = .001). A higher percentage of patients with excess weight demonstrated disturbance in their relationship with food and concerns about food and weight gain versus those with normal weight. DEAS score was positively associated with BMI, abdominal circumference, and fat mass percentage and negatively associated with lipid intake.</p><p><strong>Conclusion: </strong>Disordered eating attitudes differ in SLE patients according to nutritional status, and those with excess weight show higher DEAS scores, which may be related to food and weight gain.</p>","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"9612033251332830"},"PeriodicalIF":1.9,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143811718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thrombocytopenia and autoimmune hemolytic anemia in antiphospholipid antibody-positive patients: Descriptive analysis of the AntiPhospholipid syndrome alliance for clinical trials and InternatiOnal networking (APS ACTION) clinical database and repository (\"Registry\").","authors":"Zeynep Belce Erton, Rebecca K Leaf, Danieli de Andrade, Ann Clarke, Maria G Tektonidou, Vittorio Pengo, Savino Sciascia, Jose Pardos-Gea, Nina Kello, Diana Paredes-Ruiz, Chary Lopez-Pedrera, H Michael Belmont, Paul R Fortin, Guilherme Ramires de Jesús, Tatsuya Atsumi, Zhouli Zhang, Maria Efthymiou, D Ware Branch, Giulia Pazzola, Laura Andreoli, Alí Duarte-García, Esther Rodriguez-Almaraz, Michelle Petri, Ricard Cervera, Bahar Artim-Esen, Rosana Quintana, Hui Shi, Yu Zuo, Rohan Willis, Megan R W Barber, Leslie Skeith, Massimo Radin, PierLuigi Meroni, Maria Laura Bertolaccini, Hannah Cohen, Robert Roubey, Doruk Erkan","doi":"10.1177/09612033251332258","DOIUrl":"https://doi.org/10.1177/09612033251332258","url":null,"abstract":"<p><p>Background/PurposeAPS ACTION Registry was created to study the natural course of antiphospholipid syndrome (APS) over 10 years in persistently antiphospholipid antibody (aPL) positive patients with or without systemic autoimmune rheumatic diseases (SARDs). Our primary objective was to compare the characteristics of aPL-positive patients with or without thrombocytopenia (TP) and/or autoimmune hemolytic anemia (AIHA).MethodsThe registry inclusion criteria are positive aPL based on the Revised Sapporo APS Classification Criteria, tested at least twice within 1 year prior to enrollment. For the primary comparison of demographic, clinical, and serologic characteristics in this retrospective study, we divided patients into two groups: TP/AIHA ever and never. Thrombocytopenia was defined as a platelet count of <100,000 x 10⁹/L tested twice at least 12 weeks apart, and AIHA was defined as anemia with hemolysis and a positive direct antiglobulin test (DAT). For the secondary analysis, we compared patients with TP versus AIHA, and the immunosuppressive use stratified by systemic lupus erythematosus (SLE) classification.ResultsAs of April 2022, of 1,039 patients (primary aPL/APS: 618 [59%]; SLE classification: 334 [31%]) included in the registry, 228 (22%) had baseline (historical or current) TP and/or AIHA (TP only: 176 [17%]; AIHA only: 35 [3%], and both: 17 [2%]). Thrombocytopenia and/or AIHA was significantly associated with Asian race, SLE classification, cardiac valve disease, catastrophic/microvascular APS, triple aPL (lupus anticoagulant, anticardiolipin antibody, and anti-β₂-glycoprotein-I antibody) positivity, and SLE-related serologic and inflammatory markers. When 101/618 (16%) primary aPL/APS patients and 101/334 (34%) SLE patients with TP and/or AIHA were compared, azathioprine and mycophenolate mofetil were more commonly reported in lupus patients, however corticosteroid, intravenous immunoglobulin, and rituximab use were similar between groups.ConclusionIn our large multi-center international cohort of persistently aPL-positive patients, approximately one-fifth had active or historical TP and/or AIHA at registry entry; half of these patients had additional SLE. Cardiac valve disease, catastrophic/microvascular APS, and triple aPL-positivity were aPL-related clinical and laboratory manifestations associated with TP and/or AIHA, suggesting a more severe APS clinical phenotype in aPL-patients with TP and/or AIHA.</p>","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"9612033251332258"},"PeriodicalIF":1.9,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143780411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Implications of serum calcitonin gene-related peptide and type I interferon in systemic lupus erythematosus-associated headaches.","authors":"Shu Sugimoto, Yasuhiro Shimojima, Dai Kishida, Takanori Ichikawa, Ryota Takamatsu, Nobuyuki Yajima, Kunihiro Ichinose, Toshimasa Shimizu, Ryusuke Yoshimi, Takashi Kida, Takayuki Katsuyama, Yusuke Matsuo, Hiroshi Kajiyama, Ayuko Takatani, Yoshiki Sekijima","doi":"10.1177/09612033251332789","DOIUrl":"https://doi.org/10.1177/09612033251332789","url":null,"abstract":"<p><p>ObjectiveHeadache is a common neurological symptom in patients with systemic lupus erythematosus (SLE). Calcitonin gene-related peptide (CGRP) is a potential chemical mediator of headaches, while type I interferon (IFN) plays a pivotal role in the immune system of SLE. This study investigated the implications of CGRP and type I IFNs as headache biomarkers in patients with SLE.MethodsWe used clinical information and serum samples from 144 patients with SLE from a Japanese multicenter cohort and a biobank. Serum CGRP, IFN-α, and IFN-β levels, which were measured using enzyme-linked immunoassay, were compared among patients with headache, those without headache, and 20 healthy controls (HC). These levels were compared based on the severity of daily disability caused by headaches as determined using the Migraine Disability Assessment.ResultsOf the 144 patients, 60 had headache (median age, 42 years; 56 women) and were significantly younger than patients without headache (median age, 49 years; 77 women) (<i>p</i> < .005). Both groups had a median SLE Disease Activity Index 2000 score of 4.0, which was not significantly different, whereas photosensitivity was significantly more prevalent in patients with headache than in those without headache (<i>p</i> < .05). Serum CGRP and IFN-α levels were not significantly different between patients with headache, those without headache, and HC. Serum IFN-β levels were significantly higher in patients with headache than in those without headache (<i>p</i> < .005), while being significantly lower in both patients with and without headache than in HC (<i>p</i> < .005). No significant differences in serum CGRP, IFN-α and IFN-β levels were observed based on the severity of daily disability related to headaches.ConclusionSerum CGRP and type I IFNs levels may not be involved in SLE-associated headaches.</p>","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"9612033251332789"},"PeriodicalIF":1.9,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143780409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In-hospital outcomes of patients with antiphospholipid syndrome undergoing transcatheter and surgical aortic valve replacement: A population-based analysis of national inpatient sample from 2015-2021.","authors":"Renxi Li, Stephen J Huddleston","doi":"10.1177/09612033251322012","DOIUrl":"10.1177/09612033251322012","url":null,"abstract":"<p><p>BackgroundValvular abnormalities are common in antiphospholipid syndrome (APS). For patients who undergo aortic valve replacement (AVR), previous single institutional studies or case reports reported higher risks of mortality and thromboembolic complications among APS patients. This study aimed to investigate in-hospital outcomes of APS patients undergoing transcatheter (TAVR) and surgical aortic valve replacement (SAVR) using the largest all-payer database in the United States.MethodsPatients who underwent TAVR and SAVR were selected from National Inpatient Sample from Q4 2015-2021. Exclusion criteria were age under 18 years and concomitant procedures. Preoperative characteristics were matched between APS and non-APA patients using a 1:5 propensity-score matching in TAVR and SAVR, separately. In-hospital outcomes were examined.ResultsAfter propensity-score matching, 504 non-APS patients were matched to 100 APS patients in TAVR, while 581 non-APS patients were matched to 119 APS patients in SAVR. All outcomes between APS and non-APS patients were comparable after TAVR. In contrast, APS patients undergoing SAVR had higher risks of pulmonary embolism (PE; 5.13% vs 0.86%, <i>p</i> < .01) and acute kidney injury (AKI; 35.04% vs 22.55%, <i>p</i> = .01).ConclusionThis study represents one of the first large-scale, population-based analyses of AVR outcomes for APS patients using a national registry. APS patients had all comparable outcomes after TAVR, while they had higher risks of PE and AKI after SAVR. This highlights the necessity for close perioperative antithrombotic management and careful monitoring of renal function in APS patients. TAVR may offer a safer alternative to SAVR for appropriately selected patients, including those with APS.</p>","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"337-347"},"PeriodicalIF":1.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143458610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Summary of best evidence on self-management in adult patients with systemic lupus erythematosus.","authors":"Jiali Chen, Jiaying Chen, Zhaorong Huang, Xiaofang Chen, Erwei Sun","doi":"10.1177/09612033251325687","DOIUrl":"10.1177/09612033251325687","url":null,"abstract":"<p><p>ObjectiveTo evaluate and summarize the best evidence on self-management in adult patients with systemic lupus erythematosus (SLE) and provide evidence-based recommendations in clinical settings.MethodsLiteratures related to self-management of SLE patients were searched in the guideline websites, professional association websites and relevant databases, including clinical decisions, guidelines, expert consensus, best practice recommendations, evidence summaries, meta-analyses, systematic reviews and randomized controlled trials, etc. The search time was from January 2018 to September 2023.ResultsA total of 19 literatures were included, consisting of 9 guidelines, 4 expert consensus, 4 clinical decisions, and 2 systematic reviews, and 49 pieces of evidence were extracted. After sorting and discussing, the evidence were integrated into six aspects: skin management, diet management, exercise management, vaccination management, complication management, as well as follow-up and lifestyle management.ConclusionThe best evidence of self-management in SLE patients summarized in this study is of high quality, which can provide evidence-based recommendations for clinical medical staff and patients, so as to help self-management of SLE patients in a more scientific and effective way.</p>","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"439-451"},"PeriodicalIF":1.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143649587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A better self-efficacy is predictive of lower fatigue in systemic lupus erythematosus patients: Data from a Almenara Lupus Cohort.","authors":"Manuel F Ugarte-Gil, Rocío V Gamboa-Cárdenas, Victor Pimentel-Quiroz, Cristina Reategui-Sokolova, Claudia Elera-Fitzcarrald, Francisco Zevallos, Zoila Rodriguez-Bellido, Cesar Pastor-Asurza, Risto Perich-Campos, Graciela S Alarcón","doi":"10.1177/09612033251325320","DOIUrl":"10.1177/09612033251325320","url":null,"abstract":"<p><p><b>Objectives:</b> To determine the possible predictive value of self-efficacy on fatigue in SLE patients. <b>Methods:</b> SLE patients from a single-center prevalent cohort were included. Self-efficacy was ascertained with the five instruments of the Patient-Reported Outcomes Measurement Information System® (PROMIS®) Self-efficacy for Managing Chronic Conditions plus the PROMIS general self-efficacy. For PROMIS instruments, a score of 50 is the average for a clinical population (people with a chronic condition), the higher score, the greater self-efficacy. Fatigue was ascertained with the Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F), the higher score, the lower fatigue. Generalized estimating equations were performed, using as outcome the FACIT-F in the subsequent visit, and the self-efficacy instrument in the previous visit; multivariable models were adjusted for possible confounders. All the confounders were measured in the same visit than the self-efficacy instrument. <b>Results:</b> A total of 209 patients and 563 visits were included. At baseline, FACIT-F was 33.0 (10.2), mean general self-efficacy was 47.2 (10.4), self-efficacy for managing emotions was 44.6 (8.0), for managing symptoms was 47.7 (8.2), for managing daily activities was 45.5 (7.5) for managing social interactions was 42.9 (7.9) and for managing medications and treatment was 43.9 (7.0). In the multivariable models a lower fatigue was predicted by self-efficacy for managing symptoms and managing activities. <b>Conclusion:</b> A better self-efficacy is predictive of a subsequent lower fatigue, even after adjustment for possible confounders. Strategies to improve self-efficacy in SLE patients should be encouraged.</p>","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"519-524"},"PeriodicalIF":1.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143605659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating large language models as a supplementary patient information resource on antimalarial use in systemic lupus erythematosus.","authors":"Pamela Munguía-Realpozo, Claudia Mendoza-Pinto, Ivet Etchegaray-Morales, Edith Ramírez-Lara, Juan Carlos Solis-Poblano, Socorro Méndez-Martínez, Laura Serrano Vertiz, Jorge Ayón-Aguilar","doi":"10.1177/09612033251324501","DOIUrl":"10.1177/09612033251324501","url":null,"abstract":"<p><p>ObjectiveTo assess the accuracy, completeness, and reproducibility of Large Language Models (LLMs) (Copilot, GPT-3.5, and GPT-4) on antimalarial use in systemic lupus erythematosus (SLE).Materials and MethodsWe utilized 13 questions derived from patient surveys and common inquiries from the National Health Service. Two independent rheumatologists assessed responses from the LLMs using predefined Likert scales for accuracy, completeness, and reproducibility.ResultsThe GPT models and Copilot achieved high scores in accuracy. However, the completeness of outputs was rated at 38.5%, 55.9%, and 92.3% for Copilot, GPT-3.5, and GPT-4. When questions related to \"mechanism of action\" and \"lifestyle\", were analyzed for completeness (<i>n</i> = 8), ChatGPT-4 scored significantly higher (100%) compared to Copilot (37.5%). In contrast, questions related to \"side-effects\" (<i>n</i> = 5) scored higher for ChatGPT models than Copilot, and the differences were not statistically significant. All three LLMs demonstrated high reproducibility, with rates ranging from 84.6% to 92.3%.ConclusionsAdvanced LLMs like GPT -4 offer significant promise in enhancing patients' understanding of antimalarial therapy in SLE. Although chatbots' capability can potentially bridge the information gap patients face, the performance and limitations of such tools need further exploration to optimize their use in clinical settings.</p>","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"374-380"},"PeriodicalIF":1.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bone marrow MxA staining reflects anifrolumab response in formerly treatment-refractory systemic lupus erythematosus with initial pancytopenia.","authors":"Claus-Juergen Bauer, Joerg Wenzel, Valentin Sebastian Schäfer","doi":"10.1177/09612033251330090","DOIUrl":"https://doi.org/10.1177/09612033251330090","url":null,"abstract":"","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"9612033251330090"},"PeriodicalIF":1.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143764306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical significance of anti-Ro and Anti-La antibodies: The role of isolated anti-La.","authors":"Clara Sangüesa, Alejandro Olivé, Iñigo Rúa-Figueroa, Irene Altabás González, Julia Martinez-Barrio, María Galindo-Izquierdo, Jaime Calvo Alén, Esther Uriarte Isacelaya, Eva Tomero Muriel, Mercedes Freire González, Víctor Martínez-Taboada, Eva Salgado-Pérez, Paloma Vela, Antonio Fernández-Nebro, Javier Narváez, Raúl Menor Almagro, Gregorio Santos Soler, Javier Novoa, Ángela Pecondón, Elena Aurrecoechea Aguinaga, Oihane Ibarguengoitia, Carlos Montilla Morales, Gema Bonilla Hernán, Vicente Torrente-Segarra, Tarek Carlos Salman Monte, Mónica Ibáñez Barceló, María Jesús García-Villanueva, Rocío Caño Alameda, Joan Calvet Fontonova, Tomás Ramón Vázquez Rodríguez, Víctor Quevedo Vila, Lorena Expósito, Virginia Moreira, José Luis Andréu Sánchez, Beatriz Paredes Romero, Clara Moriano Morales, Loreto Horcada, Nuria Lozano-Rivas, Ana Pérez Gómez, José María Pego-Reigosa","doi":"10.1177/09612033251331249","DOIUrl":"https://doi.org/10.1177/09612033251331249","url":null,"abstract":"<p><p>ObjectivesThe aim of the present study was to describe demographic, clinical, and immunological characteristics of SLE patients with anti-La/SSB antibodies positive versus anti-La/SSB negative patients.MethodsRetrospective cross-sectional study, including all patients with SLE (≥4 ACR-1997 criteria) recruited in RELESSER registry. Sociodemographic, clinical, serological and comorbidities variables were collected. Anti-Ro-/La + patients were compared with the rest of the patients.ResultsIn a study involving 4219 systemic lupus erythematosus (SLE) patients, 44/3893 (1.1%) were found to be positive for isolated anti-La/SSB antibodies. The mean age was 33.77 years, with a majority being female (88.6%) and Caucasian (90.5%). The most frequent comorbidities were smoking (48.8%), dyslipidemia (47.7%), and arterial hypertension (31.8%). Photosensitivity and mucosal ulcers were more common in anti-Ro+/La + patients compared to anti-Ro+/La- and anti-Ro-/La- patients. Anti-Ro+/La + patients had a lower frequency of lupus nephritis compared to anti-Ro+/La- patients. A multivariable regression model, considering various confounding factors, was applied to compare anti-La/SSB positive patients with negative ones. Isolated anti-La/SSB positive patients showed a lower occurrence of lupus nephritis and a higher frequency of cardiac manifestations.ConclusionsThe study suggests that patients with isolated anti-La/SSB antibodies may have a unique clinical profile, with a potential protective effect against lupus nephritis but an increased likelihood of cardiac manifestations.</p>","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"9612033251331249"},"PeriodicalIF":1.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143764312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real world use of belimumab in patients with lupus nephritis.","authors":"Luxme Nadarajah, Cameron Bonthrone, Angela Pakozdi, Debasish Pyne, Andrea Cove-Smith, Ravindra Rajakariar","doi":"10.1177/09612033251325297","DOIUrl":"10.1177/09612033251325297","url":null,"abstract":"","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"435-436"},"PeriodicalIF":1.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143605660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}